Frontiers in Bioscience Research Institute and Aging
This study tests whether certain medicines and a skin treatment can slow down or partly reverse the body's aging process. As people age, the activity of their genes changes in predictable ways. Researchers can now measure a person's "biological age" from these gene-activity patterns in skin and blood. This study uses that measurement to see whether treatment can lower a person's biological age compared with their own starting point. Adults in the study take geroprotective ("age-protecting") agents by mouth or by injection. A separate skin serum containing small anti-aging peptides is applied to certain areas of skin, and those treated areas are compared with untreated areas on the same person. Skin and blood samples are taken at set times to measure biological age and markers of cell aging before, during, and after treatment. The main goal is to find out whether treatment lowers measured biological age in skin and blood. The study also looks at whether the treatments are safe and well tolerated.
This is a prospective, single-group interventional study with two treatment components, systemic and topical. Each participant contributes paired treated and untreated samples and serves as their own internal control, reducing inter-individual variability in clock measurements. Systemic component: participants receive geroprotective agents administered orally or subcutaneously. Candidate agents include metformin, low-dose chloroquine, ivermectin, and a defined nutritional supplement (collagen lysate; black seed oil or its active constituent thymoquinone; urolithin; and controlled pH modulatio…
Inclusion Criteria: * Men and women aged 50 years or older * Healthy, free of chronic or age-related disease * Not taking medication for any disease * Willing to provide blood, skin (biopsy or exfoliated cells), plucked hair, and/or saliva samples at scheduled timepoints * Able to understand and provide written informed consent Exclusion Criteria: * Age under 50 years * Pregnancy or breastfeeding * Unable to provide informed consent * Bedridden, comatose, or not coherent * Any chronic, acute, or age-related disease * Current use of any medication for a disease, including any agent with a cl…
Water-soluble anti-aging peptides applied as an aqueous serum to defined skin sites, with matched untreated contralateral/adjacent sites as within-participant controls. Peptides are selected below the \~500-Dalton stratum corneum penetration cutoff (Bos \& Meinardi, 2000): GHK-Cu \~404 Da, AHK-Cu \~418 Da, Epitalon \~390 Da, PGP \~269 Da, and CLV \~333.4 Da. Applied at approximately 1-3 mg/mL to assess reduction in START/REST transcriptomic biological age, senescence marker loss and gain of cellular fitness in treated versus untreated skin.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.